U.S. markets closed

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.4200+0.2000 (+4.74%)
At close: 04:00PM EST

Centogene N.V.

Am Strande 7
Rostock 18055
49 381 8011 3400

IndustryDiagnostics & Research
Full Time Employees660

Key Executives

NameTitlePayExercisedYear Born
Dr. Volkmar Weckesser Ph.D.Chief Information Officer & Member of Management Board877.59kN/A1968
Dr. Andrin Oswald M.D., Ph.D.Exec. Officer516.36kN/A1972
Ms. Kim StrattonInterim Chief Exec. OfficerN/AN/A1962
Mr. Rene JustCFO & MDN/AN/AN/A
Dr. Patrice P. Denefle Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Nathalie DasteChief HR OfficerN/AN/AN/A
Mr. Florian Vogel Ph.D.Chief Process OfficerN/AN/AN/A
Dr. Peter Bauer M.D.Chief Genomic OfficerN/AN/A1970
Dr. Michael MotzChief Commercial Officer of PharmaceuticalsN/AN/AN/A
Dr. Gunter Maximilian Schmid M.D.Chief Commercial Officer of DiagnosticsN/AN/A1967
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany, as well as Twist Bioscience Corporation to develop advanced sequencing tools. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

Corporate Governance

Centogene N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.